Jasper Therapeutics, Inc.
JSPR · NASDAQ
Bulios Fair Price
$0.5
12.3% downside
Current Price
$0.57
According to Bulios Fair Price, JSPR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Jasper Therapeutics, Inc. (JSPR) is a biotechnology company based in the USA that specializes in researching and developing novel therapeutic approaches in the field of hematopoiesis and cell therapy. The company focuses on treating hematological disorders and other diseases related to blood formation and the immune system. Their research centers on the use of stem cells and cell therapy to regenerate hematopoietic tissues and treat various diseases. Jasper Therapeutics aims to bring innovative and effective treatment methods that could revolutionize medical practices and improve the quality of life for patients. With the growing interest in the biotechnology industry, shares of Jasper Therapeutics, Inc. could present an intriguing investment opportunity for those who believe in the prospects of biotechnology and new therapeutic approaches.
Sector
Healthcare
Industry
Biotechnology
CEO
Jeetinder Singh Mahal
Employees
22
Headquarters
Redwood City
Upcoming events
Earnings
Upcoming earnings report